Cover Image
市場調查報告書

全球乳癌治療用單株抗體市場預測:2020年

Global Breast Cancer Monoclonal Antibodies Market Outlook 2020

出版商 KuicK Research 商品編碼 330826
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球乳癌治療用單株抗體市場預測:2020年 Global Breast Cancer Monoclonal Antibodies Market Outlook 2020
出版日期: 2015年05月22日 內容資訊: 英文 190 Pages
簡介

乳癌的發病率,在全球上升,不過,傳統的藥理學的有效性,並不是那麼高。為了克服這個問題,配合高安全性和有效性之標靶治療成為可能,乳癌治療用單株抗體登場了。

本報告提供全球乳癌治療用單株抗體市場相關調查分析、市場分析、趨勢、預測、臨床實驗平台、競爭情形等相關的系統性資訊。

第1章 單株抗體的簡介

第2章 癌症治療用單株抗體的必要性

第3章 乳癌治療用單株抗體的作用機制

第4章 全球乳癌治療用單株抗體市場分析

  • 目前市場方案
  • 乳癌治療用的臨床實驗平台概要

第5章 全球乳癌治療用單株抗體市場趨勢

  • 有正面作用的市場參數
  • 商業化的課題

第6章 全球乳癌治療用單株抗體市場未來發展預測

第7章 乳癌治療用單株抗體的臨床實驗平台:各企業、各Phase

  • 不明
  • 研究階段
  • 前臨床
  • 臨床
  • 第一階段
  • 第一階段/第二階段
  • 第二階段
  • 第三階段
  • 已認證

第8章 已上市乳癌治療用單株抗體臨床考察

第9章 臨床實驗平台上中止、中斷的乳癌治療用單株抗體:各企業、各Phase

  • 中止
  • 沒有開發報告

第10章 競爭情形

  • Amgen
  • Biocad
  • Biocon
  • Celltrion Pharm
  • CuraGen Corporation
  • Dyax Corp
  • GlaxoSmithKline
  • ImmunoGen
  • MacroGenics
  • Merck
  • Merrimack Pharmaceuticals
  • Novartis
  • Pierre Fabre
  • Pfizer
  • Recombio
  • Roche Holding
  • Samsung Bioepis
  • Synthon

圖表

目錄

Breast cancer incidences are increasing across the globe and conventional therapeutics have modest pharmacological efficacy. To surmount this issue, investigators came forth with monoclonal antibodies for breast cancer treatment which have targeted capabilities along with higher safety and efficacy levels. They have found that some receptors have overexpressed in cancerous cells due to which they could be identified and targeted. Monoclonal antibodies are highly customizable due to specific nature they eliminate cancerous cells while sparing normal cells during breast cancer treatment. Their use in neoadjuvant and adjuvant therapy has been successfully checked by investigators. Some the breast cancer monoclonal antibodies are also used in first-line and second-line treatment. Moreover, they are also compatible with chemotherapeutics due to which they are commonly used in combinatorial therapy. In future, investigators are expected to find new monoclonal antibody formulations offering better medical care to breast cancer patients.

Breast cancer segment consists of few monoclonal antibodies and chemotherapeutics seems to dominate the landscape. Hormone therapy and kinase inhibitors are other major segment which has been widely prescribed by physicians. Emerging technologies, personalized breast cancer vaccine, has also started to make niche in breast cancer segment. This scenario reflects that breast cancer monoclonal antibodies have to witness severe competition in global market. Despite lesser in number, they generate significant revenues due to which pharmaceutical companies are actively engaged in their research and development. They have decreased the market shares of chemotherapeutics and significantly decreased the profit margins of other drug categories. They are likely to dominate the breast cancer segment as they have been accepted as mainstream treatment and they have also become indispensible part of combinatorial therapies.

Globally, Roche seems to dominate the breast cancer monoclonal antibody segment because of largest inventory. Its block buster molecule, Herceptin has been able to dominate this segment for several years. It was found that breast cancer cells become recalcitrant and relapsed condition could not be treated with Herceptin. This finding propelled the development of other monoclonal antibodies to overcome these shortcomings. They have been formulated using variants of Her 2 that has been found to be associates with around quarter of breast cancer cases. They are also used in various combinations due to which they have been able to increase the survival rates and progression free disease survival. On the other hand, introduction of different products by same company for same cancer indication has created competition within the products. As a result, few products generate more sales as compared to other like Herceptin while products like Perjeta which are used in second line treatment generate modes sales.

India, Europe and Australia have been proposed as major market where biosimilar breast cancer monoclonal antibodies would be marketed in incipient stages. These market have different characteristic features due to which they are expected to witness different sales of biosimilar breast cancer monoclonal antibodies. Europe is likely to become an important market due to stringent healthcare budget and maintenance of sustainable healthcare system. European Medicine Agency (EMA) have already granted marketing approval to many biosimilar products. This shows that biosimilar breast cancer monoclonal antibodies are likely to generate significant revenues in European market. Indian market may face slightly slow market growth due to patent issues. However, such issues are expected to be resolved in coming years leading to higher sales. Large population size and escalating breast cancer incidences along with affordable pricing are expected to generate more sales of biosimilar breast cancer monoclonal antibodies. Australia has also shown positive response for these drugs and they are like to import it from countries like India where high production could be achieved at competitive pricing. US market is also likely to open in coming years due to which this category would observe significant growth. In this way, the future of breast cancer monoclonal antibodies seems to be optimistic.

" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:

  • Breast Cancer Monoclonal Antibodies Mechanism
  • Global Breast Cancer Monoclonal Antibody Market Analysis
  • Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
  • Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
  • Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
  • Marketed Breast Cancer Monoclonal Antibodies: 6 mAb

Marketed Breast Cancer Monoclonal Antibodies Clinical Insight

  • Bevacizumab (Avastin®)
  • Pertuzumab (Omnitarg, Perjeta®)
  • Trastuzumab (Herceptin®)
  • Trastuzumab Biosimilar (Hertraz™ & CANMAb™)
  • Trastuzumab Emtansine (Kadcyla®)
  • Trastuzumab Subcutaneous (Herceptin®)

Table of Contents

1. Introduction to Monoclonal Antibodies

  • 1.1 History of Development of Monoclonal Antibodies
  • 1.2 Working of Monoclonal Antibodies

2. Need for Monoclonal Antibodies for Cancer Treatment

3. Breast Cancer Monoclonal Antibodies Mechanism

4. Global Breast Cancer Monoclonal Antibody Market Analysis

  • 4.1 Current Market Scenario
  • 4.2 Breast Cancer Pipeline Overview

5. Global Breast Cancer Monoclonal Antibody Market Dynamics

  • 5.1 Favorable Market Parameters
  • 5.2 Commercialization Challenges

6. Global Breast Cancer Monoclonal Antibodies Market Future Prospects

7. Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase

  • 7.1 Unknown
  • 7.2 Research
  • 7.3 Preclinical
  • 7.4 Clinical
  • 7.5 Phase I
  • 7.6 Phase I/II
  • 7.7 Phase II
  • 7.8 Phase III
  • 7.9 Registered

8. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight

  • 8.1 Bevacizumab (Avastin®)
  • 8.2 Pertuzumab (Omnitarg, Perjeta®)
  • 8.3 Trastuzumab (Herceptin®)
  • 8.4 Trastuzumab Biosimilar (Hertraz™ & CANMAb™)
  • 8.5 Trastuzumab Emtansine (Kadcyla®)
  • 8.6 Trastuzumab Subcutaneous (Herceptin®)

9. Discontinued & Suspended Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase

  • 9.1 Discontinued
  • 9.2 No Development Reported

10. Competitive Landscape

  • 10.1 Amgen
  • 10.2 Biocad
  • 10.3 Biocon
  • 10.4 Celltrion Pharm
  • 10.5 CuraGen Corporation
  • 10.6 Dyax Corp
  • 10.7 GlaxoSmithKline
  • 10.8 ImmunoGen
  • 10.9 MacroGenics
  • 10.10 Merck
  • 10.11 Merrimack Pharmaceuticals
  • 10.12 Novartis
  • 10.13 Pierre Fabre
  • 10.14 Pfizer
  • 10.15 Recombio
  • 10.16 Roche Holding
  • 10.17 Samsung Bioepis
  • 10.18 Synthon

List of Figures

  • Figure 1-1: History of Development of Monoclonal Antibodies
  • Figure 1-2: Working of Monoclonal Antibodies
  • Figure 3-1: Mechanism of Bevacizumab
  • Figure 3-2: Mechanism of Denosumab
  • Figure 3-3: Mechanism of Trastuzumab
  • Figure 3-4: Mechanism of Trastuzumab Emtansine
  • Figure 3-5: Mechanism of Pertuzumab
  • Figure 4-1: Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
  • Figure 4-2: Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
  • Figure 4-3: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
  • Figure 4-4: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
  • Figure 4-5: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
  • Figure 4-6: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
  • Figure 5-1: Global Breast Cancer Monoclonal Antibody Market Favorable Parameters
  • Figure 5-2: Breast Cancer Monoclonal Antibodies Commercialization Challenges
  • Figure 10-1: Amgen Clinical Pipeline
  • Figure 10-2: Biocon Clinical Pipeline
  • Figure 10-3: Celltrion Clinical Pipeline
  • Figure 10-4: MacroGenics Clinical Pipeline
  • Figure 10-5: Novartis Clinical Pipeline
  • Figure 10-6: Synthon Clinical Pipeline

List of Tables

  • Table 2-1: Breast Cancer Monoclonal Antibodies Available in Global Market
  • Table 2-2: Herceptin Biosimilars Available in Global Market
Back to Top